Healthy Returns: AstraZeneca cholesterol pill shows promise as race with Merck heats up

1. AstraZeneca shows promising data on its experimental oral PCSK9 inhibitor. 2. The new pill significantly lowers LDL cholesterol by nearly 51% after 12 weeks. 3. Goldman Sachs projects PECK9 sales could reach $12 billion by 2034. 4. AstraZeneca's pill may democratize access to cholesterol treatment compared to injections. 5. Merck's oral PCSK9 inhibitor may be more effective, but AstraZeneca's offers convenience.